Grants for Nonprofits - Science and Technology

The mission of the Arizona Department of Health Services (ADHS) Arizona Biomedical Research Centre (ABRC) is to identify and support innovative biomedical research to improve the health of all Arizonans. ABRC is focused on leveraging existing resources, maximizing partnerships, cultivating communication, and promoting innovation. ABRC manages multiple initiatives which are guided by input from leaders and professionals from Arizona’s universities, nonprofit research institutions, hospitals, medical centers, and patient advocacy groups. Financial Notes: Funding Source: The funding source for this Grant is the Health Research Fund (Tobacco Tax) as established by Arizona Revised Statute (ARS) §36-275 (https://www.azleg.gov/ars/36/00275.htm) and §36-773  (https://www.azleg.gov/ars/36/00773.htm). Up to $3,500,000 per year is available for Arizona Investigator Grant (AZ IG) and New Investigator Award (NIA) applications. The maximum award for AZ IG Applications is $225,000.00 annually with a maximum project duration of three (3) years from the award date. The maximum award for NIA Applications is $75,000.00 annually with a maximum project duration of three (3) years from the award date.

This funding opportunity provides financial support to California non-profits and Native American tribes for projects aimed at improving community air quality through education, technical training, and targeted emission reduction strategies.

The Catalyst Endowment Fund, managed by the Hartford Foundation for Public Giving, is offering a competitive funding opportunity centered on "Empowering Future Leaders and Community Builders through Youth Sports in Greater Hartford." This initiative aligns with the foundation's broader mission to foster well-being and development within the community. The program aims to leverage the positive effects of youth sports, such as developing teamwork, leadership, and promoting physical and mental health, to create resilient, confident, and empowered individuals. The fund's focus on bridging access gaps to youth sports directly supports the foundation's strategic priority of creating sustainable support systems for the region's youth. The primary beneficiaries of this grant program are youth in Greater Hartford, particularly those in underserved communities who face barriers to accessing sports programs. The overarching impact goal is to empower these young individuals, transforming them into future leaders and community builders. By focusing on sustainable support systems, the program seeks to create lasting positive change beyond the grant duration, addressing systemic inequalities in access to enriching activities. This aligns with a theory of change that posits that providing equitable opportunities in youth sports will lead to enhanced individual development and stronger, more engaged communities. The program's priorities and focus areas are clearly defined to achieve these goals. Infrastructure Development aims to improve existing sports facilities and equipment, ensuring long-term accessibility. Training and Capacity Building initiatives will equip coaches, volunteers, and staff with the skills to deliver high-quality programs, fostering a robust support network. Partnerships and Collaborations are encouraged to strengthen relationships with schools, community organizations, and local businesses, pooling resources and support. Finally, Health and Wellness Integration seeks to embed physical and mental health services within youth sports, promoting holistic well-being and sustained participation. Expected outcomes and measurable results include improved accessibility to youth sports in underserved communities, an increased number of trained coaches and volunteers, stronger community partnerships supporting youth sports, and enhanced physical and mental well-being among participants. The program anticipates fostering increased participation in youth sports, leading to the development of critical life skills such as leadership, teamwork, and resilience. Ultimately, the Hartford Foundation for Public Giving expects these initiatives to contribute to a more equitable and vibrant Greater Hartford, producing a generation of empowered individuals who are prepared to lead and build their communities. The fund has $69,000 available to award, with one or more grants totaling this amount, contingent on the project's size, funding need, and the quality of the proposals submitted in response to the forthcoming Request for Proposal.

This funding opportunity supports innovative research projects aimed at making significant advancements in breast cancer prevention, diagnosis, and treatment, involving collaboration with breast cancer survivors as advocates.

This funding opportunity provides up to $5,000 for neighborhood groups in Montgomery County to implement projects that enhance community pride and improve quality of life through collaboration with local government.

This program provides funding to rural health care providers in North Carolina to enhance telehealth services and improve access to care for underserved communities.

Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) 2024 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 14, 2024. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates (Tables 2 and 3), a table that provides a very top level summary of proposal contents (Table 1), and the full text of the ROSES-2024 "Summary of Solicitation", may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2024. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2024table2 and http://solicitation.nasaprs.com/ROSES2024table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH24ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on C.8 Lunar Data Analysis Program (.pdf) to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read C.1 Planetary Science Research Program Overview (.pdf) from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the division overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2024 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at sara@nasa.gov, but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2024 blog feed for amendments, clarifications, and corrections to at https://science.nasa.gov/researchers/solicitations/roses-2024/, and (3) The ROSES-2024 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).

Despite huge advances in the development of novel medical therapies, Americans still live with poor health outcomes and suffer from the ill-effects of disease. Current medical research and the medical delivery system in the United States focus primarily on the reactive treatment of illnesses, despite the fact that many diseases or their ill-effects are preventable.The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Specifically, PHO hypothesizes that 1) population-level improvements in access to and uptake of disease prevention and wellness-promoting behaviors and 2) development of novel early-detection methods and prophylactic interventions could drastically improve the health of American throughout their lives, and 3) that system level innovations are required for delivery of proactive health effectively. Specific PHO interest areas include:Novel prevention, detection and prophylactic treatment methods for disease: Novel and scalable methods for early detection of disease and illness including the use of low/no-cost sensing modalities. Prophylactic approaches to prevention of diseases and harmful disease outcomes. Methods for continuous and widespread sensing of health state and early disease indicators that can be deployed at population-scale.Population-level approaches to increase the adoption of prevention and wellness behaviors: Early indicators of disease and pre-disease states and measures associated with proactive health outcomes that are both inexpensive and effective. Low-cost, high-uptake mental health resiliency and mindfulness building methods for individuals. Methods to inform and educate individuals about healthy behaviors including lifestyle and preventative medical measures. Methods that incentivize individuals to adopt and maintain healthy behaviors. Novel approaches to increasing individual healthspan and independence even in the absence of disease.System innovation for the delivery of proactive health outcomes: Novel, robust and predictive surrogates for long-term health outcomes with associated epidemiological models. Valuation models for long-term treatment effects for vaccination, screening and other public health interventions. New funding and delivery models for preventative intervention.Other high-quality submissions that propose revolutionary technologies that meet the goals of PHO will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy advocacy, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The Lake County Community Foundation Fall Grant focuses on two key priority areas: Leadership Development and Animal Welfare. The Foundation's mission is aligned with fostering a stronger nonprofit sector through leadership development opportunities that benefit Lake County's broader nonprofit community, rather than individual organizations. For animal welfare, the Foundation, through the Lake County Humane Society Fund, seeks to cultivate innovative approaches and address unmet needs for animals in Lake County. This grant embodies the Foundation's commitment to strategic investments that strengthen the community. Within Leadership Development, the Foundation prioritizes projects that build a pipeline of competent, emerging leaders for the county's nonprofit sector. A crucial aspect is increasing access to quality programming for leaders of color and other underrepresented groups, ensuring a diverse and inclusive leadership base. The ultimate goal is to equip leaders to better serve their nonprofit organizations, clients, and communities, thereby amplifying their collective impact across Lake County. This approach reflects the Foundation's theory of change, which posits that investing in leadership capacity will lead to more effective and sustainable social impact. For Animal Welfare, the grant targets organizations dedicated to the needs of animals in Lake County. The focus is on innovative approaches to support animal welfare and addressing needs where the applicant is the sole service provider. This area aligns with the Foundation's broader aim of addressing critical community needs and fostering a compassionate environment for all residents, including animals. The expected outcome is improved animal welfare through targeted interventions and support for organizations making a significant difference in this area. The Foundation's strategic pillars of Economic Justice, Community Ownership, and Rapid Community Response guide the evaluation criteria for all applications. Successful proposals will demonstrate alignment with these pillars and respond to high-priority needs identified by current Lake County data. The Foundation also emphasizes diversity and equity within applicant organizations, seeking staff, leadership, and boards that reflect the communities they serve. Furthermore, strong, documented partnerships, the potential to leverage other resources, and a high probability of affecting significant change over the next three years are key considerations, along with cost-effective service delivery and a proven track record of achieving outcomes. These criteria underscore the Foundation's commitment to impactful, sustainable change.

This funding opportunity provides financial support for research projects that aim to improve the inclusion, independence, and quality of life for individuals with disabilities, particularly focusing on underserved populations and critical issues affecting these communities.

This funding opportunity supports U.S.-based researchers and organizations in developing innovative space weather forecasting tools and applications that meet the needs of operational users like NOAA and the Department of Defense.

This funding opportunity supports educational institutions, nonprofits, and government agencies in Hawaiʻi to develop projects that boost local business growth, job creation, and sustainability on the island.

This funding opportunity provides financial support for innovative projects that develop and scale up biofuel technologies, particularly for transportation sectors that are hard to electrify, with a focus on reducing greenhouse gas emissions and promoting environmental justice.

This funding opportunity provides $5 million to support the deployment and commercialization of innovative technologies in public transportation, aimed at federal, state, local, and tribal governments, as well as public transit providers and educational institutions.

The National Aeronautics and Space Administration (NASA) Headquarters has released a solicitation, titled Early Stage Innovations (ESI), as an appendix to the Space Technology Mission Directorate (STMD) umbrella NASA Research Announcement (NRA) titled "Space Technology Research, Development, Demonstration, and Infusion 2024 (SpaceTech REDDI 2024), on April 4, 2024. The ESI solicitation is available by opening the NSPIRES homepage at https://nspires.nasaprs.com/, selecting Open under "Solicitations," and searching "Early Stage Innovations (ESI24)" under Keywords. The Space Technology Research Grants (STRG) Program within STMD seeks proposals from accredited U.S. universities to develop unique, disruptive, or transformational space technologies that have the potential to lead to dramatic improvements at the system level performance, weight, cost, reliability, operational simplicity, or other figures of merit associated with spaceflight hardware or missions. The projected impact at the system level must be substantial and clearly identified. Only accredited U.S. universities are eligible to submit proposals. Teaming is permitted see solicitation for complete eligibility requirements as well as teaming restrictions. A Principal Investigator (see solicitation for restrictions) or Co-Investigator may participate in no more than two proposals in response to this solicitation. NASA encourages submission of ESI proposals on behalf of tenure-track or tenured faculty members at all U.S. universities and especially encourages proposals submitted on behalf of and/or that include as team members women, members of underrepresented minority groups, and persons with disabilities. The solicitation exclusively seeks proposals that are responsive to one of the following two topics: Topic 1 Computational Materials Engineering for Lunar Metals Welding Topic 2 Passive Lunar Dust Control through Advanced Materials and Surface Engineering NASA anticipates addressing other topics in future ESI Appendix releases. The financial and programmatic support for ESI comes from the Space Technology Research Grants Program within the Space Technology Mission Directorate. Awards are planned to start in January 2025. NASA plans to make approximately 6 awards as a result of this ESI solicitation, subject to the receipt of meritorious proposals. The actual number of awards will depend on the quality of the proposals received; NASA reserves the right to make no awards under this solicitation. STMD is strongly committed to ensuring that proposal review is performed in an equitable and fair manner that reduces the impacts of any unconscious biases. To this end, this Appendix will employ a Dual-Anonymous Peer Review (DAPR) process to evaluate proposals. Using DAPR, not only are proposers not told the identities of the reviewers, but the identities of the proposers (personnel and organization names) will not be shared with the reviewers until after the technical review of all anonymized proposals has been completed. All proposals must be submitted electronically through NSPIRES by an authorized organizational representative. Notices of Intent (strongly encouraged) are due by May 9, 2024, with proposals due on or before June 6, 2024, 5 pm Eastern. Detailed submission instructions and due dates are provided in the solicitation. Potential proposers and their proposing organizations are urged to familiarize themselves with the submission system, ensure they are registered in NSPIRES, and submit the required proposal materials well in advance of the deadline. All technical and programmatic comments and questions may be addressed by email to the Space Technology Research Grants Program Executive, at hq-esi-call@mail.nasa.gov. Responses to inquiries will be answered by email and may also be included in the Frequently Asked Questions (FAQ) documents located on the NSPIRES page associated with the solicitation; anonymity of persons/institutions who submit questions will be preserved.

This grant provides financial assistance for transportation to local baseball and hockey games for accredited schools and nonprofit organizations in northwest Ohio and southeast Michigan that demonstrate a need.

The Pennsylvania HOME-American Rescue Plan Supportive Services (HOME-ARP SS) funds can provide a broad range of supportive services to individuals and families that meet one of the qualifying populations as defined in Notice CPD-21-10: Requirements for the Use of Funds in the HOME-American Rescue Plan Program. Supportive services may be provided to individuals and families who are not already receiving the services outlined in the Notice through another program. Applicants may establish a separate supportive services activity or activities or may combine supportive services with other HOME-ARP activities. Notice CPD-21-10: Requirements for the Use of Funds in the HOME-American Rescue Plan Program HOME-ARP funding is provided by the U.S. Department of Housing and Urban Development (HUD) and administered by DCED. Financial Info: The minimum funding request for Supportive Services projects is $25,000. Up to 5% may be requested for administrative costs.

This ISO seeks solution summaries and proposal submissions for projects that fall within the general scope of the ARPA-H Health Science Futures (HSF) mission office. HSF expands what is technically possible by developing approaches that will remove the scientific and technological limitations that stymie progress towards the healthcare of the future. HSF supports cutting-edge, often disease-agnostic research programs that have the potential for translational real-world change.Considering the current healthcare challenges that we face today, the goal of achieving better health outcomes is a moving target that requires daring and adaptable solutions. HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support:Breakthrough Technologies: Paradigm shifting technologies that will change how we approach the diagnosis, treatment, and impact of diseases and conditions. Novel approaches to improve maternal and fetal medicine, decrease maternal morbidity and mortality during birth, and the post-partum period. Efforts should include new technology to monitor, detect, and/or treat maternal and/or fetal complications with less invasive and traumatic methods. Foundational advances in genetic, epigenetic, cellular, tissue, and organ replacement therapies that enable personalized medical interventions at scale in a manner that is accessible, cost-effective, and designed to impact the communities of greatest need. Interventions that target and reverse disease pathogenesis and/or enhance plasticity to address diseases of the nervous, neuromuscular, skeletal, lymphatic, cardiovascular, and other organ systems. Novel approaches to diagnose and treat diseases of the lymphatic system, particularly rare diseases, with a focus on the effects of genetic expression in the lymphatic system and/or models demonstrating the relationship between lymphatic dysfunction and health and disease.Transformative Tools: Novel, agile solutions that will move from bench to bedside quickly, facilitating revolutionary advances in medical care. Development of tools that counter idiosyncratic, off-target, or chronic effects of medicines that are commonly used or that are being used experimentally to treat or prevent disease. Development of bionics to restore sight, hearing, taste, or smell. Site-selective neuromodulation to regulate specific physiological functions and treat chronic health conditions such as inflammation, pain, and metabolic or endocrine disorders. Synthetic biology approaches to diagnosing, treating, and/or curing a multitude of diseases. Novel physics and/or chemistry-based approaches to improve imaging that reduces cost, increases availability, expands capability, improves resolution, reduces exposure to radiation, and accommodates pediatric patient populations. Integrated sensing and delivery devices for treating and diagnosing chronic health conditions, including mental health conditions or substance use disorders. Miniaturization of complex hardware to enable broader access to pediatric and other patient populations, as well as portability, such as diagnostic, treatment, imaging, or other devices.Platform Systems: Adaptable, multi-application systems and technologies that are reconfigurable for a wide variety of clinical needs Novel molecular platform approaches, including the modulation of host systems, delivery to targets with spatial and temporal precision, and mitigation of off-target effects to accelerate interventions that dramatically improve health outcomes. New approaches to accelerate and routinize mammalian and microbial cellular engineering to enable next generation therapeutic applications, develop multiscale interventions, and automate hypothesis generation and discovery to expand those applications to disease states in which cellular therapies have not traditionally been employed. Innovative approaches at the intersection of artificial intelligence, high performance computing (including quantum computing) and biological systems, including enabling de novo design of biomolecules with entirely new phenotypes.Other high-quality submissions that propose revolutionary technologies that meet the goals of HSF will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy changes, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The FY24 PCRP Early Investigator Research Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers under the guidance of one or more designated mentors. This opportunity allows early-career investigators to develop a research project, investigate a problem or question in prostate cancer research, and further their intellectual development as prostate cancer researchers of the future. All application components for the FY24 PCRP Early Investigator Research Award are to be written by the Principal Investigator (PI), with appropriate direction from the mentor(s).Key elements of this award mechanism are as follows: Principal Investigator: The postdoctoral investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of prostate cancer research; however, the PI is not required to have previous prostate cancer research experience. The PI must have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training) as of March 31, 2025. The PCRP strongly encourages applications from PIs who demonstrate a commitment to pursuing a career focused on prostate cancer health disparity research. Mentor(s): Applications must include at least one mentor appropriate to the proposed research project who has experience in prostate cancer research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The primary mentor can be a junior faculty member, in which case the PI is encouraged to include a secondary mentor with a more robust track record in prostate cancer research and mentorship. Applications that focus on prostate cancer health disparity should include at least one mentor with experience in prostate cancer health disparity research. The selected mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a prostate cancer researcher. Research Approach: Proposed research ideas are required to address one or more of the FY24 PCRP Overarching Challenges. Projects that specifically address the FY24 PCRP Overarching Challenge to advance health equity and reduce disparities in prostate cancer are strongly encouraged. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. Inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the PI, mentor(s), or member(s) of the collaborating team. Additionally, required resources should be identified and supported through documentation. Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity. Researcher Development Plan: The PI must outline an individualized, prostate cancer-focused researcher development plan, which should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PIs development as an independent prostate cancer researcher. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PIs institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Early Investigator Research Award should not exceed $300,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $6.24M to fund approximately 13 Early Investigator Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports clinical research projects that extend or enhance existing breast cancer studies, requiring collaboration with consumer advocates to improve outcomes for patients and the community.